Cancer Research UK, Illumina sign sequencing technology deal for lung cancer trial
Posted: November 27, 2014 at 5:43 pm
PBR Staff Writer Published 27 November 2014
Cancer Research UK has signed a supply agreement with Illumina to use its gene sequencing technology in a Phase IIa lung cancer clinical trial in the UK that aims to advance personalized medicine.
As part of the deal, Illumina will provide its research use only Nextera Rapid Capture Enrichment kits and NGS technology to a multi-arm, early-stage National Lung Matrix Trial being run by Cancer Research UK.
The National Lung Matrix trial is being conducted by Cancer Research UK and professor Gary Middleton is its chief investigator.
Cancer Research UK head of Stratified Medicine Dr Ian Walker said: "Personalising cancer treatments, by matching patients with the targeted treatments that are most likely to work for them, could transform the lives of people with the disease.
"Genetic sequencing will provide the information that allows us to routinely pair-up patients with this more targeted approach. This is at the very heart of the vision for precision cancer medicine."
"This collaboration will help our researchers to quickly identify the genetic faults underpinning a patient's cancer. The goal is to then use this information to deliver what we hope will be an effective treatment."
The results will allow investigators to stratify patients and place them into the most appropriate arm of the trial.
In order to provide the targeted treatments for each arm of the Matrix Trial, AstraZeneca and Pfizer are also partnering with Cancer Research UK.
Read the original here:
Cancer Research UK, Illumina sign sequencing technology deal for lung cancer trial